welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Microlin Bio to Acquire Nucleic Acid Therapeutic Assets of Marina Biotech
Microlin Bio, Inc., a development stage biotechnology company focused on the development of microRNA based therapeutics for cancer, and Marina Biotech, Inc., a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced that the companies have executed a term sheet under which Microlin intends to acquire Marina’s nucleic acid therapeutics assets.
expertly curated content related to this topic
- Patrick M. Lynch, JD, MDDr. Patrick Lynch grew up in a Lynch s...
- Elizabeth A. Montgomery, MDDr. Elizabeth Anne Montgomery is a profe...
- Mitchell W. DillonSenior Certified Genetic Counselor at Mo...
- Collecting Information From Patients and Family Members With Hereditary Colorectal Cancer Syndromes or Who Are at Hi...RATIONALE: Gathering medical and fam...
- Vanderbilt – Ingram Cancer CenterVanderbilt-Ingram Cancer Center is one o...
- Jatin Roper, MDJatin Roper, MD, is the Assistant Profes...
- Janice L. Berliner, MSJanice has been a clinical genetic couns...
English
Portuguese
Spanish